top of page

Beyond Dopamine: What do we know about Parkinson's Disease?



"Neuroinflammation plays a role" is one of those sentences that sounds like an explanation, but as inflammation has been an ongoing buzzword, it functions more like a shrug. It is true. It's also true of nearly every chronic disease on the books. So what does it actually mean is driving Parkinson's disease (PD) and I think what my patients and I wonder is what does our current knowledge mean for where we can intervene? So let's look at it.


  • Who gets Parkinson's?

  • What do we know about the mechanism?

  • What does it mean for opportunities?


Who Gets Parkinson's Disease?

I'll share something with you. In the last year, I found out I am part of the APOE 3 & 4 crew who are 6x more likely to develop Alzheimer's Disease. You know what I don't have in my family history at all? Alzheimer's. You know what I do have in my family history? Parkinson's.


Age is the dominant risk factor, full stop. Incidence rises sharply after 60, and PD is fundamentally a disease of the aging nervous system layered on top of everything else on this list. Sex matters too. In prevalence studies, males are diagnosed at meaningfully higher rates than females. The reasons are still debated, such as estrogen's antioxidant properties, occupational exposure differences, and X-linked genetic effects. They all have some support, but nothing has won.



There are a few other major PD-associated genes, PINK1, Parkin, and DJ-1, all function in mitophagy, the cell's process for identifying and clearing damaged mitochondria. That's not a coincidental detail. It means the genetic route into PD and the environmental-toxin route (below) can converge on the same mitochondrial pathway through two different doors, one inherited, one encountered.


The majority of PD is not explained by any single gene we've found. If you're waiting for a genetic test to tell you your risk, for most people it won't.

Environmental exposure is where the evidence has gotten considerably stronger in recent years, and it's the subject of a notable new book, The Parkinson's Plan, by Dr. Ray Dorsey and Dr. Michael Okun. Their argument, built on decades of research, is that specific chemical exposures, paraquat and other pesticides, the industrial solvent trichloroethylene (TCE), and air pollution, are meaningful and modifiable drivers of PD risk. This is legitimate research from credentialed movement-disorder specialists, and it's reshaping how the field talks about prevention. The data is genuinely encouraging, and PD remains a multifactorial disease where no single exposure explains most cases.


Some things to know:

  • Well water use, occupational or residential pesticide exposure, and TCE-contaminated groundwater are worth knowing about as risk markers, not just occupational hazards for farmers.

  • Head trauma raises risk, though the effect size is smaller than most people assume from headlines alone.

  • Prodromal signals are increasingly taken seriously:

    • chronic constipation,

    • loss of sense of smell, and

    • REM sleep behavior disorder (acting out dreams physically during sleep) can precede a PD diagnosis by years to decades.

  • Essential tremor (ET) is worth naming as its own risk marker. This is an action tremor, present when the hands are being used or held in a sustained position, not the classic PD rest tremor. Patients with ET are roughly four times more likely to develop PD than those without it. The relationship isn't well understood as causal, more likely a shared or overlapping neurodegenerative vulnerability, but it's worth naming rather than dismissing ET as purely benign.



The Why: The Mechanisms, Ranked


Alpha-synuclein Misfolding into Lewy Bodies & Aggregation

This is the closest to a root cause. PD is defined pathologically by the accumulation of misfolded alpha-synuclein protein into Lewy bodies inside neurons. This is the through-line that connects almost everything else.


Gut First Hypothesis


Mitochondrial Dysfunction & Oxidative Stress

This area is stronger, and it explains selective vulnerability. This is where the environmental exposure data, the genetic data above, and the cellular mechanism data all meet. The classic PD toxin model, MPTP/MPP+, is a well-established mitochondrial complex I inhibitor, and complex I activity is measurably reduced in the substantia nigra of PD patients. Paraquat is more complicated than it's usually presented, and this is a case where the more careful, mechanistic literature has actually moved past the popular framing rather than merely questioning it. Paraquat was long assumed to work the same way as MPTP, by inhibiting complex I, on the strength of its structural similarity.


But a genetic knockout study found that removing complex I activity entirely did not protect dopaminergic neurons from paraquat, rotenone, or MPP+ toxicity, directly contradicting what the complex-I hypothesis would predict, and this finding has held up well in the literature since. The actual mechanism looks to run through oxidative stress and JNK-pathway activation instead, a related but mechanistically distinct route, further supported by work identifying JNK3 specifically as the key mediator. What the heck is JNK3? It's a stress-response enzyme that gets switched on by the oxidative damage itself. Once activated, it travels into the mitochondria and helps flip on the cell's self-destruct sequence. This isn't cleanup or recycling, it's an active kill signal. In animal models, removing JNK3 entirely protects dopaminergic neurons from these same toxins, which is good evidence it's driving the damage rather than just showing up at the scene.


The takeaway for the mitochondrial-vulnerability story doesn't change, oxidative damage to substantia nigra neurons is still central, and paraquat is still a legitimate environmental risk factor. But the specific "paraquat blocks complex I like MPTP does" line that shows up in a lot of wellness content is more outdated than contested at this point.

Why the substantia nigra specifically? The honest answer is that it's the intersection of everything above: dopaminergic neurons there have unusually high metabolic demand (long, densely branched axons), comparatively low antioxidant buffering capacity, and, per the Braak hypothesis, however contested, a plausible anatomical route for pathological protein to arrive there first via the vagus nerve. High demand, low defenses, and possibly first in line. That combination is the leading explanation for why this one circuit takes the hit that other regions don't.


Neuroinflammation = Amplifier, Not Ignition

This is the tier that gets flattened into "neuroinflammation plays a role" everywhere else. It's true, but the more accurate framing is that neuroinflammation (microglial activation, cytokine release) largely responds to and amplifies damage that's already underway from misfolded protein and oxidative stress, rather than initiating the disease process on its own. It matters for symptom progression and is a legitimate treatment target, but it's downstream, not upstream.


Who are the key mediators for inflammation to watch for?

You don't need to be a biologist, but treat these as keywords you'll use for future searches.


NF-κB is the master switch,

not just one mediator among many. It's a transcription factor, not a cytokine itself, and it sits upstream of most of the others. When it's activated (in microglia, and even in dopaminergic neurons themselves), it turns on the genes for the pro-inflammatory cytokines below. One postmortem study found NF-κB activity elevated more than 70-fold in the brain tissue of PD patients compared to controls. Blocking NF-κB activation protects dopaminergic neurons in animal models, which is fairly strong evidence it's doing real damage, not just correlating with it.


The core cytokines NF-κB switches on:

The upstream trigger: the NLRP3 inflammasome.

This is a protein complex that assembles inside activated microglia in response to danger signals, misfolded alpha-synuclein fibrils are one of the specific triggers, and its job is to activate an enzyme (caspase-1) that processes IL-1β into its active form. It's become one of the more promising drug targets in PD research specifically because it sits at the junction between "alpha-synuclein pathology" and "inflammatory cytokine release," tying the first and third mechanisms above together.

Microglia are the cell doing most of this, not neurons themselves. They're the brain's resident immune cells, and in PD they shift from a surveillance/protective state into a chronically activated, cytokine-releasing state that's classically shorthanded as the "M1" phenotype (this M1/M2 framing is a simplification the field increasingly qualifies, but it's still the common shorthand in the literature).


Supplements: Signal vs. Noise

Mucuna pruriens (Velvet Beans)

This one is different from the others because it isn't really a "supplement" in the usual sense. It's a natural source of L-DOPA itself, with real, measurable pharmacological activity, not a precursor or a vague antioxidant. That's exactly why it needs a firm caution flag: dosing varies widely and unpredictably between preparations, and it can interact directly with prescribed dopaminergic medication (carbidopa-levodopa), either compounding effects unpredictably or complicating a clinician's ability to titrate the actual medication. Make sure your neurologist always has an up to date list of any supplements you are taking.


L-Tyrosine

This is a case where the mechanistic story sounds better than it holds up. Tyrosine is the amino acid precursor to dopamine, so the logic of "supplement the precursor to make more dopamine" seems intuitive. Two problems. First, in PD, the rate-limiting step in dopamine synthesis is the enzyme tyrosine hydroxylase, which is what's failing as dopaminergic neurons are lost, not a shortage of raw material. Adding more precursor doesn't fix a broken conversion step. Think: I Love Lucy, the chocolate episode.


Second, and more clinically important: tyrosine is a large neutral amino acid, and it competes directly with levodopa medication for the same transport system, LAT1, both across the gut wall and at the blood-brain barrier. This is the same well-documented mechanism behind the standard clinical advice to separate levodopa from high-protein meals. Taking tyrosine alongside carbidopa-levodopa risks reducing the medication's absorption and effectiveness. For anyone on levodopa therapy, this isn't a neutral add-on, it can actively work against the prescribed treatment.


CoQ10

Mechanistically plausible (mitochondrial cofactor, antioxidant), and an earlier small trial suggested benefit. Then, the phase III QE3 trial, 600 participants, high dose, well-designed, was stopped early for futility: no benefit at 1200mg or 2400mg/day, with a slight adverse trend in both active groups compared to placebo. On the one hand, the larger, better-designed trial contradicted the smaller promising one, which is exactly the pattern that should make you trust the larger trial more.


However, when you look at the inclusion and exclusion criteria, they did not include folks on medication. Participants were excluded if they'd used any PD medication in the prior 60 days, or used symptomatic PD medication for more than 90 days total. It is unclear if anyone might have given up medication to be able to join the trial. Moreover, the mean baseline UPDRS was 22.7, Hoehn and Yahr stage ≤2.5. This is genuinely early/mild disease by design. It could be that the impact of supplements like CoQ10 is stage specific. Meaning, if it is more helpful to more progressed conditions, you would not see that here. There's a note there about an adverse trend. It's important to remember it's a progressive illness, so without medication, I would be hoping for a slowed progression at most, not no progression. More research is needed, but I wanted to include this as an example of how a large, clean study may not give the straightforward picture you think.


Berberine

Mechanistically one of the more interesting entries here, and worth taking seriously as a research direction rather than dismissing as another trendy metabolic supplement. Animal and cell-culture studies show berberine protecting dopaminergic neurons from oxidative stress and mitochondrial dysfunction via the AMPK-SIRT1-PGC-1α signaling pathway, the same axis implicated in tier 2 above, and improving motor outcomes in 6-OHDA toxin models of PD. That's a real, mechanistically coherent story.


The catch: this is entirely preclinical. There are no human PD trials yet, only animal and cell models. And berberine carries a genuinely significant drug interaction profile, it inhibits CYP3A4, CYP2D6, and CYP2C9, the same liver enzymes responsible for metabolizing a long list of common medications. For a population that is often on multiple prescriptions (dopaminergic agents, antidepressants, blood pressure medication), this interaction risk is not theoretical. Mechanistically promising, clinically premature, and it needs a real medication review before anyone with PD starts it.


And going back to our I Love Lucy, a 2025 rotenone rat model study found that berberine combined with caffeine normalized tyrosine hydroxylase levels alongside reducing inflammatory cytokines and alpha-synuclein aggregation, essentially preserving the population of dopamine-producing neurons rather than acting on the enzyme directly. A few things, 1. this was tested as a combination with caffeine, not berberine alone. That's a real, mechanistically coherent story. 2. is the catch: This is entirely preclinical. There are no human PD trials yet, only animal and cell models. AND berberine carries a genuinely significant drug interaction profile, it inhibits CYP3A4, CYP2D6, and CYP2C9, the same liver enzymes responsible for metabolizing a long list of common medications. For a population that is often on multiple prescriptions (dopaminergic agents, antidepressants, blood pressure medication), this interaction risk is not theoretical.


Vitamin D


Omega-3

This is a go-to supplement for the brain. It has modest evidence, mostly resting on general anti-inflammatory mechanisms rather than PD-specific trial data. Reasonable as part of a broader anti-inflammatory approach, not a targeted intervention.


NAC (N-acetylcysteine)

The rationale (glutathione precursor, supports the same oxidative stress pathway implicated in tier 2 mechanisms above) is sound on paper, but human PD-specific outcome data is still early-stage. Plausible, not proven.

 

Dr. Diane Stanley is a doctor of acupuncture and Chinese medicine. Blog content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making changes to your health routine.


References

Comments

bottom of page